✦ LIBER ✦

Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation

✍ Scribed by Heikki Makisalo; Anu Koivusalo; Anne Vakkuri; Krister Hockerstedt

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 81 KB
Volume: 10
Category: Article
ISSN: 1527-6465
DOI: 10.1002/lt.20153

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sildenafil monotherapy in portopulmonary

Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation

✍ Anna R. Hemnes; Ivan M. Robbins 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB

Portopulmonary hypertension (POPH), or pulmonary arterial hypertension associated with cirrhosis, carries a high mortality and often precludes liver transplantation. Many POPH patients have preserved or increased cardiac output; therefore, decreasing pulmonary artery pressure rather than improving c

Successful outcomes following living don

Successful outcomes following living donor liver transplantation for portopulmonary hypertension

✍ Mahesh Bandara; Fredric D. Gordon; Akmal Sarwar; M. Elizabeth Knauft; Elizabeth 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB

Pulmonary arterial hypertension (PAH) associated with portal hypertension [portopulmonary hypertension (PPHTN)] occurs in 2% to 10% of patients with advanced liver disease and carries a very poor prognosis without treatment. Most hepatic transplantation centers consider moderate to severe PPHTN to b

Clinical predictors of pulmonary hyperte

Clinical predictors of pulmonary hypertension in patients undergoing liver transplant evaluation

✍ Nektarios D. Pilatis; Larry E. Jacobs; Pairoj Rerkpattanapipat; Morris N. Kotler 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Clinical prediction of portopulmonary hypertension (PPHTN) is critical in the preoperative evaluation of candidates for orthotopic liver transplantation (OLT) because of its association with significant morbidity and mortality. To determine the clinical, laboratory, and echocardiographic predictors

Successful treatment of severe portopulm

Successful treatment of severe portopulmonary hypertension in a patient with Child C cirrhosis by Sildenafil

✍ José Luis Callejas Rubio; Javier Salmerón Escobar; Jorge González-Calvín; Norber 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB

Successful adult-to-adult living donor l

Successful adult-to-adult living donor liver transplantation in a patient with moderate to severe portopulmonary hypertension

✍ Hideaki Uchiyama; Yuji Soejima; Akinobu Taketomi; Tomoharu Yoshizumi; Noboru Har 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 1 views

Portopulmonary hypertension (PPHTN) is one of the most devastating consequences of end-stage liver cirrhosis. When a patient has moderate to severe PPHTN, his or her candidature for liver transplantation is denied. Here we report a successful adult-to-adult living donor liver transplantation (LDLT)

Safety and efficacy of combined use of s

Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension

✍ Mark J. Austin; Neil I. McDougall; Julia A. Wendon; Elizabeth Sizer; Alex S. Kni 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

Portopulmonary hypertension (PPHTN) represents a constrictive pulmonary vasculopathy in patients with portal hypertension. Liver transplantation (LT) may be curative and is usually restricted to patients with mild-to-moderate disease severity characterized by a mean pulmonary artery pressure (mPAP <